vdt
6 months ago
Biotech Catches Massive Premarket Bid
By: Tomas Ronolski - AllPennyStocks.com News
Wednesday, October 11, 2023
A New Jersey-based biotech company is catching a serious premarket bid this morning following a press release detailing the company’s announcement that they completed clinical resolution of a patient’s recurrent hemorrhagic cystitis due to Candida krusei, a fluconazole inherited resistant fungal pathogen, following treatment with the company’s MAT2203.
Traders immediately got excited about this news, as shares of Matinas Biopharma Holdings Inc. (NYSE American: MTNB) are currently bid up at $0.2693/share (+73.74% implied open for sellers) at the time of writing. This should be an exciting session for this micro cap!
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.
Copyright © 2023 AllPennyStocks.com. All rights reserved.
vdt
6 months ago
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.
Matinas’ lead which although highly potent, can be associated with significant toxicity. Matinas’ LNC platform provides oral delivery of amphotericin B without the significant nephrotoxicity otherwise associated with IV-delivered formulations. MAT2203 also allows for safe, longer-term use outside of a hospital setting, which could have substantial favorable pharmacoeconomic impact. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 will be further evaluated as an oral step-down monotherapy treatment following IV AMB in a single pivotal Phase 3 study in the treatment of aspergillosis in persons with limited treatment options who are unable to be treated with azoles for reasons related to drug-drug interactions, resistance or for whom these antifungal agents are unable to be used for other clinical reasons.
In addition to MAT2203, preclinical and clinical data have demonstrated that this novel technology can potentially provide solutions to many of the challenges standing in the way of achieving safe and effective intracellular delivery of both small molecules and larger, more complex molecular cargos such as RNAi, antisense oligonucleotides, and vaccines. The combination of its unique mechanism of action and flexibility with routes of administration (including oral) positions Matinas’ LNC technology to potentially become a preferred next-generation orally available intracellular drug delivery platform. For more information, please visit www.matinasbiopharma.com.
Forward-looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, intellectual property rights, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 as well as other documents filed by the Company from time to time thereafter with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
vdt
6 months ago
CONFERENCE TODAY Oct.12 and THURSDAY Oct. 19 next week
September 28 2023 - 07:00AM
GlobeNewswire Inc.
Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:
Dawson James Small Cap Growth Conference being held Thursday, October 12 at the Wyndham Grand Harborside Hotel in Jupiter, Fla. The presentation is scheduled for 3:30 p.m. Eastern time.
The ThinkEquity Conference being held Thursday, October 19 at the Mandarin Oriental Hotel in New York City.
The presentation is scheduled for 11:00 a.m. Eastern time.
A webcast of the presentation at the Dawson James Small Cap Growth Conference will be available live on the IR Calendar page of the Investors section of the company’s website. The webcast will be archived for 90 days. Institutional investors interested in arranging a meeting with Matinas BioPharma management, please contact Jody Cain at LHA investor relations at jcain@lhai.com.
vdt
6 months ago
Try to HOLD. This is a good stock.
Take a look: who are the financial institution
large shareholders of MTNB?
Largest shareholders include
Vanguard Group Inc, VTSMX
Vanguard Total Stock Market Index Fund Investor Shares,
Sargent Investment Group, LLC, BlackRock Inc.,
VEXMX - Vanguard Extended Market Index Fund Investor Shares,
Geode Capital Management, Llc,
Arkadios Wealth Advisors,
Neville Rodie & Shaw Inc,
FSMAX - Fidelity ...
2 CONFERENCES IN OCTOBER 2023
crudeoil24
6 months ago
Huge conference starts today. > It's exciting to share the ongoing, consistent positive clinical impact of our broad-spectrum, fast-acting oral MAT2203, especially with a major infectious disease conference, IDWeek, kicking off today," said Theresa Matkovits, PhD, Chief Development Officer at Matinas. "We look forward to advancing MAT2203 into a Phase 3 registration trial to evaluate its potential in patients suffering from invasive aspergillosis who have limited or no treatment options. We believe that oral, effective, and safe MAT2203, if approved, would represent a dramatic improvement to current clinical standard of care and become the treatment of choice for patients and physicians battling invasive fungal infections. We are grateful to the participants in our Expanded Access program and to their physicians for recognizing the clinical potential of MAT2203 in treating a broad spectrum of invasive fungal infections."
subslover
6 months ago
Huge News = Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
BEDMINSTER, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces complete clinical resolution of a patient’s recurrent hemorrhagic cystitis due to Candida krusei (C. krusei), a fluconazole inherited resistant fungal pathogen, following treatment with MAT2203, Matinas’ oral formulation of the potent antifungal amphotericin B. This patient was treated under Matinas’ Expanded Access/Compassionate Use Program by Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan.
“We are thrilled with the positive clinical impact MAT2203 had on this extremely ill patient with limited treatment options,” said Dr. Miceli. “This 61-year-old male with a history of diabetes, kidney disease, chronic obstructive lung disease, and coronary heart disease with heart failure had developed recurrent hemorrhagic cystitis due to C. krusei. In this case, neither an echinocandin nor a second-generation triazole was an option due to their inability to deliver adequate drug levels in urine. Treatment with IV-amphotericin B deoxycholate was quickly discontinued due to renal toxicity and we transitioned this patient to MAT2203, which was well-tolerated with no adverse effects. Treatment with MAT2203 led to complete resolution of his symptoms and improvement of his kidney function to baseline. Ultimately, the patient’s urine culture was negative for C. krusei after just 14 days of treatment with MAT2203.”
A total of 11 patients with no other treatment options are currently receiving or have completed treatment with MAT2203 under this program, and several additional cases are under consideration. In each instance, the patient was not responding to or was resistant to azole therapy or was unable to receive azole therapy due to drug/drug interactions. All patients who experienced serious renal toxicity while receiving IV-amphotericin B who were subsequently treated with MAT2203 saw their renal toxicity reversed and renal function return to normal.
“It’s exciting to share the ongoing, consistent positive clinical impact of our broad-spectrum, fast-acting oral MAT2203, especially with a major infectious disease conference, IDWeek, kicking off today,” said Theresa Matkovits, PhD, Chief Development Officer at Matinas. “We look forward to advancing MAT2203 into a Phase 3 registration trial to evaluate its potential in patients suffering from invasive aspergillosis who have limited or no treatment options. We believe that oral, effective, and safe MAT2203, if approved, would represent a dramatic improvement to current clinical standard of care and become the treatment of choice for patients and physicians battling invasive fungal infections. We are grateful to the participants in our Expanded Access program and to their physicians for recognizing the clinical potential of MAT2203 in treating a broad spectrum of invasive fungal infections.”
MAT2203 is not yet licensed or approved anywhere globally.
About MAT2203
Matinas BioPharma is developing MAT2203 as a potential oral broad-spectrum treatment for invasive deadly fungal infections. Although amphotericin B is a fungicidal agent, it is currently only available through an intravenous route of administration, which is known to be associated with a number of significant safety issues such as renal toxicity and anemia due to very high circulating levels of amphotericin B. MAT2203 has the potential to overcome the significant limitations of the currently available amphotericin B products due to its targeted oral delivery, combining comparable fungicidal activity with targeted delivery resulting in a lower risk of toxicity and potentially creating the ideal antifungal agent for the treatment of invasive fungal infections. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 will be further evaluated as an oral step-down monotherapy treatment following IV-amphotericin B in a single pivotal Phase 3 study in the treatment of aspergillosis in persons with limited treatment options who are unable to be treated with azoles for reasons related to drug-drug interactions, resistance or for whom these antifungal agents are unable to be used for other clinical reasons.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.
Matinas’ lead LNC-based therapy is MAT2203, an oral formulation of the broad-spectrum antifungal drug amphotericin B. In addition to MAT2203, preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges standing in the way of achieving safe and effective intracellular delivery of both small molecules and larger, more complex molecular cargos such as RNAi, antisense oligonucleotides, and vaccines. The combination of its unique mechanism of action and flexibility with routes of administration (including oral) positions Matinas’ LNC technology to potentially become a preferred next-generation orally available intracellular drug delivery platform. For more information, please visit www.matinasbiopharma.com.
Forward-looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to our business activities, our strategy and plans, the future development of its product candidates, including MAT2203, the Company’s ability to identify and pursue development, licensing and partnership opportunities for its products, including MAT2203, or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking
vdt
7 months ago
Matinas BioPharma to Present at Two Investment Conferences in October 2023
September 28, 2023 7:00am EDT
BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:
Dawson James Small Cap Growth Conference being held Thursday, October 12 at the Wyndham Grand Harborside Hotel in Jupiter, Fla. The presentation is scheduled for 3:30 p.m. Eastern time.
The ThinkEquity Conference being held Thursday, October 19 at the Mandarin Oriental Hotel in New York City. The presentation is scheduled for 11:00 a.m. Eastern time.
A webcast of the presentation at the Dawson James Small Cap Growth Conference will be available live on the IR Calendar page of the Investors section of the company’s website. The webcast will be archived for 90 days.
Institutional investors interested in arranging a meeting with Matinas BioPharma management, please contact Jody Cain at LHA investor relations at jcain@lhai.com.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.
Matinas’ lead LNC-based therapy is MAT2203, an oral formulation of the broad-spectrum antifungal drug amphotericin B, which although highly potent, can be associated with significant toxicity. Matinas’ LNC platform provides oral delivery of amphotericin B without the significant nephrotoxicity otherwise associated with IV-delivered formulations. MAT2203 also allows for safe, longer-term use outside of a hospital setting, which could have substantial favorable pharmacoeconomic impact. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in cryptococcal meningitis, meeting its primary endpoint and achieving robust survival.
MAT2203 will be further evaluated as an oral step-down monotherapy treatment following IV AMB in a single pivotal Phase 3 study in the treatment of aspergillosis in persons with limited treatment options who are unable to be treated with azoles for reasons related to drug-drug interactions, resistance or for whom these antifungal agents are unable to be used for other clinical reasons.
In addition to MAT2203, preclinical and clinical data have demonstrated that this novel technology can potentially provide solutions to many of the challenges standing in the way of achieving safe and effective intracellular delivery of both small molecules and larger, more complex molecular cargos such as RNAi, antisense oligonucleotides, and vaccines. The combination of its unique mechanism of action and flexibility with routes of administration (including oral) positions Matinas’ LNC technology to potentially become a preferred next-generation orally available intracellular drug delivery platform. For more information, please visit www.matinasbiopharma.com.
(...)
Investor Contact
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
vdt
7 months ago
Looking for a bright future for MTNB$$: MAT 2203 as a viable drug, and Matinas as a promising company, and could garner interest from potential partners.
-------------
Matinas deserves congratulations for getting publication of the ENACT trial results in a per reviewed journal. Unfortunately, the position taken by the FDA regarding a Phase 3 trial for MAT 2203 for invasive fungal infections has made to impractical for Matinas to conduct such a study. In light of this setback, I think it would make sense for Matinas to go back to the original plan—a Phase 3 pivotal trial for CM. Approval for this indication would validate MAT 2203 as a viable drug, and Matinas as a promising company, and could garner interest from potential partners.
While sales for CM would likely be modest, MAT 2203 could possibly be used off label for other indications that would help to validate the use of MAT 2203 for other IFI (along with the LPAD pathway).
Matinas sorely needs a “W,” and getting approval of MAT 2203 for some indication could be the win it needs to get positive recognition and possible funding.
LM
Register for real-time alerts, custom portfolio, and market movers
gail
6 months ago
Zardiw
6 months ago
NEXT
6 months ago
Eagle1
6 months ago
Golden Cross
6 months ago
Hot Features
Premium
